| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
183,678,000 |
| Market
Cap: |
6.41(B) |
| Last
Volume: |
775,760 |
Avg
Vol: |
770,146 |
| 52
Week Range: |
$26.13 - $36 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Delivery |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 793 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Alkermes is a biopharmaceutical company. Co. has a portfolio of marketed products focused on central nervous system disorders such as addiction and schizophrenia and a pipeline of product candidates in the fields of neuroscience and oncology. Co.'s proprietary products include: ARISTADA, which is an extended-release intramuscular injectable suspension approved in the U.S. for the treatment of schizophrenia; ARISTADA INITIO, which is indicated for the initiation of ARISTADA when used for the treatment of schizophrenia in adults; and VIVITROL, which is for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
83,200 |
101,200 |
464,215 |
742,886 |
| Total Sell Value |
$2,800,263 |
$3,357,481 |
$15,661,831 |
$24,365,188 |
| Total People Sold |
2 |
2 |
4 |
5 |
| Total Sell Transactions |
5 |
7 |
14 |
25 |
| End Date |
2025-11-09 |
2025-08-08 |
2025-02-07 |
2024-02-08 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Pops Richard F |
Director and CEO, Alkermes plc |
• • – |
2026-02-05 |
4 |
D |
$33.55 |
$2,087,817 |
D/D |
(62,230) |
1,377,740 |
|
- |
|
| Pops Richard F |
Director and CEO, Alkermes plc |
• • – |
2026-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
149,580 |
1,439,970 |
|
- |
|
| Gaffin David Joseph |
EVP, CLO, Alkermes, Inc. |
• • – |
2026-02-05 |
4 |
D |
$33.55 |
$255,617 |
D/D |
(7,619) |
223,107 |
|
- |
|
| Gaffin David Joseph |
EVP, CLO, Alkermes, Inc. |
• • – |
2026-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
25,352 |
230,726 |
|
- |
|
| Hopkinson Craig C. |
EVP R&D, Chief Medical Officer |
• • – |
2026-02-05 |
4 |
D |
$33.55 |
$250,082 |
D/D |
(7,454) |
75,638 |
|
- |
|
| Hopkinson Craig C. |
EVP R&D, Chief Medical Officer |
• • – |
2026-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
25,352 |
83,092 |
|
- |
|
| Nichols Christian Todd |
SVP, Chief Commercial Officer |
• • – |
2026-02-05 |
4 |
D |
$33.55 |
$214,351 |
D/D |
(6,389) |
100,946 |
|
- |
|
| Nichols Christian Todd |
SVP, Chief Commercial Officer |
• • – |
2026-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
21,127 |
107,335 |
|
- |
|
| Jackson Blair Curtis |
EVP, Chief Operating Officer |
• • – |
2026-02-05 |
4 |
D |
$33.55 |
$289,402 |
D/D |
(8,626) |
221,552 |
|
- |
|
| Jackson Blair Curtis |
EVP, Chief Operating Officer |
• • – |
2026-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
28,810 |
230,178 |
|
- |
|
| Cooke Shane |
Director |
• • – |
2026-02-02 |
4 |
AS |
$34.34 |
$2,115,673 |
D/D |
(61,200) |
103,744 |
|
- |
|
| Cooke Shane |
Director |
• • – |
2026-02-02 |
4 |
OE |
$31.64 |
$1,936,368 |
D/D |
61,200 |
164,944 |
|
- |
|
| Hopkinson Craig C. |
EVP R&D, Chief Medical Officer |
• • – |
2026-02-02 |
4 |
AS |
$33.54 |
$305,385 |
D/D |
(9,000) |
57,740 |
|
- |
|
| Hopkinson Craig C. |
EVP R&D, Chief Medical Officer |
• • – |
2026-02-02 |
4 |
OE |
$19.34 |
$96,700 |
D/D |
5,000 |
66,740 |
|
- |
|
| Hopkinson Craig C. |
EVP R&D, Chief Medical Officer |
• • – |
2026-01-08 |
4 |
AS |
$30.00 |
$150,005 |
D/D |
(5,000) |
61,740 |
|
14% |
|
| Hopkinson Craig C. |
EVP R&D, Chief Medical Officer |
• • – |
2026-01-08 |
4 |
OE |
$19.34 |
$96,700 |
D/D |
5,000 |
66,740 |
|
- |
|
| Hopkinson Craig C. |
EVP R&D, Chief Medical Officer |
• • – |
2026-01-02 |
4 |
AS |
$28.00 |
$112,000 |
D/D |
(4,000) |
61,740 |
|
20% |
|
| Hopkinson Craig C. |
EVP R&D, Chief Medical Officer |
• • – |
2025-12-01 |
4 |
AS |
$29.30 |
$117,200 |
D/D |
(4,000) |
65,740 |
|
17% |
|
| Hopkinson Craig C. |
EVP R&D, Chief Medical Officer |
• • – |
2025-11-03 |
4 |
AS |
$30.38 |
$273,442 |
D/D |
(9,000) |
69,740 |
|
12% |
|
| Hopkinson Craig C. |
EVP R&D, Chief Medical Officer |
• • – |
2025-11-03 |
4 |
OE |
$19.34 |
$96,700 |
D/D |
5,000 |
78,740 |
|
- |
|
| Hopkinson Craig C. |
EVP R&D, Chief Medical Officer |
• • – |
2025-10-15 |
4 |
AS |
$31.53 |
$283,776 |
D/D |
(9,000) |
73,740 |
|
5% |
|
| Hopkinson Craig C. |
EVP R&D, Chief Medical Officer |
• • – |
2025-10-15 |
4 |
OE |
$19.34 |
$96,700 |
D/D |
5,000 |
82,740 |
|
- |
|
| Gaffin David Joseph |
EVP, CLO, Alkermes, Inc. |
• • – |
2025-08-03 |
4 |
D |
$26.55 |
$23,762 |
D/D |
(895) |
205,374 |
|
- |
|
| Gaffin David Joseph |
EVP, CLO, Alkermes, Inc. |
• • – |
2025-08-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,014 |
206,269 |
|
- |
|
| Nichols Christian Todd |
SVP, Chief Commercial Officer |
• • – |
2025-06-10 |
4 |
AS |
$31.09 |
$103,654 |
D/D |
(3,334) |
86,208 |
|
-3% |
|
1182 Records found
|
|
Page 1 of 48 |
|
|
1.36 (4.05%) 
